AZ bags Almirall lung drugs
Enlarge image


AZ bags Almirall lung drugs

31.07.2014 - Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

After recently fending off takeover attempts by US rival Pfizer, British-Swedish drug maker Astrazeneca is eager to show it can pull its own weight with a multimillion euro lung drug deal with Spanish rival Almirall. Astrazeneca said it would initially pay €653m for the rights the respiratory franchise of Barcelona-based Almirall, including drugs in development. The deal could net Almirall another €896m if development, launch and sales milestones are met.

AZ made around €950m in respiratory drug sales in the first quarter of 2014, mainly from its two products Symbicort and Pulmicort. The respiratory business is a "key growth platform" for AZ, and Almirall’s drugs will significantly bolster it. The transaction, which is expected to complete by the end of 2014, includes revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies. Apart from Eklira (aclidinium), which is already on the market, the franchise includes LAS40464, the combination of aclidinium with formoterol which has been filed for registration in the EU, LAS100977 (abediterol), a once-daily long-acting beta2-agonist in Phase II and several pre-clinical programmes. Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of inhalation devices, will also transfer to Astrazeneca. The companies anticipate that a significant number of employees dedicated to the respiratory business  - which includes Almirall Sofotec employees - will make the shift to Astrazeneca.

This is just one of a number of partnerships AZ has recently launched in their business with respiratory drugs. Just within the last few days, the company announced a collaboration with Swiss Roche to develop a plasma-based companion diagnostic test to support AZ’s investigational compound for non-small-cell lung cancer and a collaboration with Netherlands-based Qiagen to develop a diagnostic test to identify non-small cell lung cancer patients who are suitable for treatment with AZ's drug Iressa; and last month, the pharma company signed a licence agreement with Synairgen for its experimental asthma drug SNG001.



30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.


29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.


25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.


23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.


21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).


17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.


16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.


15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.


11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

© 2007-2014 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%


  • ANTISOMA (UK)1.32 GBP-14.84%
  • NOVACYT (F)4.46 EUR-10.26%


  • WILEX (D)2.82 EUR243.9%
  • Allergy Therapeutics (UK)20.00 GBP34.4%


  • HYBRIGENICS (F)1.72 EUR-28.0%
  • PROSENSA (NL)9.67 USD-23.4%
  • PROTHENA PLC (IE)17.79 USD-21.1%


  • SANTHERA (CH)59.90 CHF2836.3%
  • PAION (D)2.42 EUR272.3%


  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • PROSENSA (NL)9.67 USD-70.9%

No liability assumed, Date: 31.07.2014